Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease. (31st January 2018)

• Record Type: Journal Article
• Authors: Wylie, Scott A.; van Wouwe, Nelleke C.; Godfrey, Steven G.; Bissett, Patrick G.; Logan, Gordon D.; Kanoff, Kristen E.; Claassen, Daniel O.; Neimat, Joseph S.; van den Wildenberg, Wery P.M.
• Is Part Of: Neuropsychologia. Volume 109(2018)
• Page Start: 262
• Page End: 269
• Publication Date: 2018-01-31
• Subjects: Parkinson's disease -- Stop-signal inhibition -- Dopamine -- Inhibitory control; Neuropsychology -- Periodicals; Neurology -- Periodicals; Psychophysiology -- Periodicals; Neuropsychologie -- Périodiques; Neuropsychology; Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.neuropsychologia.2017.12.032
• Languages: English
• ISSNs: 0028-3932

Abstract

Abstract: The present behavioral study delineates the impact of Parkinson's disease (PD) and of dopaminergic medication on action control over voluntary behavior. Previous studies reported either prolonged responding or stopping latencies in PD compared to healthy controls (HC). Few studies investigated the effects of dopaminergic medication on these processes concurrently. We administered a stop-change task, an extended version of the stop task, that required (i) speeded responding to a go signal (i.e., going), (ii) inhibiting ongoing motor responses (i.e., stopping), and (iii) changing to an alternative response. PD performance (n = 33) was collected once during regular dopaminergic medication conditions (On state) and once after a medication washout period (Off state). A group of age-matched HC (n = 21) performed the stop-change task once. Response latencies to go signals were comparable between HC and PD Off, indicative of unimpaired going. Compared to HC, PD Off showed prolonged stopping latencies. Within the clinical group, stopping latencies significantly improved after taking dopaminergic medication. Interestingly, the shorter stopping latencies observed in the On state were paralleled by longer response latencies to go signals. The degree of the inhibition improvement observed in the medication state was correlated with the degree of response slowing. Change RT did not vary between groups or between medication states. These patterns of results are discussed in terms of a tradeoff between going versus stopping of motor responses in PD patients. Shifts of this tradeoff seem to be driven by dopaminergic medication, which has potential clinical implications. Highlights: Dopamine withdrawn PD patients exhibit slower stopping compared to healthy controls. PD patients show a significant tradeoff between going and stopping that is modulated by dopamine. Dopamine medication in PD shifts performance control towards slower responding to the benefit of inhibitory control.